Fazila Rajab, BDS

Investigators assessed the efficacy of BsAb5003 in treating multiple myeloma, with the results showing that the therapy may be an effective treatment approach.

CAR T-cells specifically targeting FCRL5, when integrated with IL-15, may improve cytotoxicity, thereby enhancing the therapeutic potency of these cells.

Precision therapies, although effective in earlier stages, may not work later.